A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)

Investigator: Eric Bernicker, MD

Study Coordinator: Juan Morales Viera

Status: Enrolling

ClinicalTrials.gov Number: NCT03968419

Phone: 786.803.2333

Protocol Number: PRO00023822

Description

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor microenvironment changes on treatment by comparing pre-, on- and post-treatment samples will be evaluated
More to Explore